Cytori Therapeutics (CYTX) is a not yet profitable marketer of tissue regeneration therapies based in San Diego. Cytori's proprietary platform employs adipose-derived stem and regenerative cells (ADRCs). The company receives regular revenues from sales of its Puregraft, and other systems to researchers and healthcare providers around the world. Cytori's product, and research grant revenue streams partially fund its investments into clinical development of its cell therapies for cardiovascular and burn therapies.
Pumped up for cardiovascular therapies
Cytori's future hangs heavily on the development of its cardiovascular disease therapeutic pipeline. Myocardial ischemia is a disease characterized by insufficient blood supply to heart muscle caused by a rupture along the coronary artery. Cytori, of course, would like to market its...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: